

Intrasense strengthens its portfolio with the signature of a contract with SATT Sud-Est, the Medical Imaging Unit of the Assistance Publique Hôpitaux de Marseille and Aix Marseille University

Montpellier, France, March, 27 2023 06:00 pm CEST

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions, announces the signature of a technology transfer contract with SATT Sud-Est which will allow the company to acquire artificial intelligence algorithms dedicated to the detection of pulmonary nodules in radiology. These algorithms were developed by the Medical Imaging Unit of the Assistance Publique Hôpitaux de Marseille (PIM/APHM), the Biological and Medical Magnetic Resonance Center (CRMBM) and the Mathematics Institute of Marseille (I2M).

Artificial intelligence serving the fight against lung cancer

Lung cancer is the second most common cancer in the world and is a global public health priority. Intrasense participates in this fight by designing detection, monitoring and analysis tools, key steps in the management of a cancer often diagnosed at a late stage. In February 2022, the French National Authority for Health reminded us of the importance of screening for this cancer and recommended the implementation of screening programs in France using low-dose CT scanners for at-risk populations. The number of new lung cancers is rising sharply each year worldwide, leading to a significant increase in the use of CT scans.

In this context, artificial intelligence tools will help improve the service provided to the patient by the radiologist and optimize the interpretation time of the examinations. The program implemented by the teams of this project is part of a more general objective to offer radiologists and their patients a tool that simplifies decision making and secures the diagnosis of pulmonary parenchymal nodules.

Expansion of Intrasense's product portfolio

In this context, Intrasense has signed a contract with SATT Sud-Est, which provides for a technology transfer dedicated to the detection of nodular and micronodular lesions of the lung parenchyma, to enrich its solutions dedicated to the diagnosis and monitoring of lung cancer. After the development phase, jointly supported by the PIM/APHM, the CRMBM, the IMM and the SATT, the objective is now to industrialize the technology.

Intrasense's objective is to validate the algorithm in clinical and regulatory terms and then to integrate this cutting-edge tool into its oncology solution currently under development. Radiologists will benefit from a nodular and micronodular lesion detection tool that is seamlessly integrated into their daily workflow and meets the needs of screening, therapeutic follow-up and clinical decision making for each patient. The algorithms will be integrated into the Myrian product line in a second phase

The AI algorithm for detecting lung lesions was developed by a multidisciplinary team coordinated by Prof. Badih Ghattas, Professor at Aix-Marseille University, and Prof. Alexis Jacquier, Head of the Radiology Department at the Timone University Hospital (APHM-AMU) and researcher at the CRMBM.

Prof. Alexis Jacquier explains: "The first foundations of this work were developed during the Covid crisis to accelerate diagnosis and better predict the severity of Covid-related lung damage. This work allowed us to put this AI tool into production within the hospital from July 2020. Then we contacted the SATT to help us protect and promote our scientific work. The SATT, whose mission is the transfer of innovative technologies, was interested and supported us in the search for an industrial partner whose desires and needs were in line with our vision of AI. This contract shows all the dynamics around artificial intelligence in radiology as well as the opportunities offered to build a collaboration between industrials and academics. This project will be greatly accelerated by the IAM-APHM/IA platform recently acquired by the PIM and the APHM. This platform is the first one allowing the design, validation and orchestration of AI projects in radiology within a healthcare institution in France. Our goal is for all of these radiology AI innovations to benefit from rapid integration into the workflow of our APHM radiology services."

"We are very pleased to collaborate with PIM/APHM, CRMBM, I2M and SATT Sud-Est. The acquisition of new artificial intelligence algorithms in a field as crucial as lung cancer allows us to meet the expectations of radiologists and thus offer them a complete solution adapted to their needs. This new partnership is perfectly in line with our strategic plan. This acquisition of artificial intelligence technology complements the licensing agreements already signed and the partnerships underway, thus completing the group's technological portfolio," said Nicolas Reymond, CEO of Intrasense.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device, Myrian®, a software platform that facilitates and secures diagnosis, decision making and therapeutic follow-up.

Thanks to Myrian®, more than 1,000 healthcare institutions in 40 countries benefit from a single, integrated platform for reading all types of images (MRI, CT, etc.). Enriched with expert clinical applications for specific pathologies, Myrian® offers a universal image

processing solution that can be integrated into all healthcare information systems. Intrasense has 55 employees, including 20 dedicated to Research and Development. Labelled as an "innovative company" by the BPI, it has invested more than 12 million euros in Research and Development since its creation.

More information on www.intrasense.fr.

About SATT Sud-Est

A Technology Transfer Company (SATT) helps companies of all sizes to innovate through the transfer of technologies from public research institutions.

It is the transmission link between the knowledge produced by researchers in public research laboratories in the South and Corsica regions and the socio-economic world. Helping companies to support their innovations by giving them access to French public research, one of the best in the world. Thus enabling them to innovate while limiting the risks.

SATT South East offers market analysis, legal protection, development from technological maturity to proof of concept, and finally marketing and licensing. SATT South East also provides training to its shareholder institutions.

In addition, SATT South East diagnoses the needs of innovation in companies as part of the Doctors from South program, a specific program to promote the recruitment of young doctors in companies.

More information on www.sattse.com

About AP-HM

With 4 hospital sites, a logistics platform and 12 training institutes, the Public Assistance - Marseille Hospitals (AP-HM) is the third largest hospital and university center (CHU) in France and the largest hospital in the Provence - Alpes - Côte d'Azur region (France).

Its missions are care, training, research, prevention and health education. The AP-HM is also a support institution for the GHT

The AP-HM is also a support institution for the "Provence Hospitals" GHT, which brings together the 13 public establishments in the Bouches du Rhône department and includes the Laveran Army Training Hospital. It is also the region's largest employer, with

18,000 professionals, including 8,500 nurses and 2,000 doctors. Its hospitals cover the full range of hospital care: medicine, surgery, obstetrics, psychiatry, follow-up care and rehabilitation, children and adults. They offer medical care ranging from local care to cutting-edge treatments of excellence for rare and complex pathologies. They develop cutting-edge research, with a constant desire to improve the quality of care for hospitalized patients and their families. The AP-HM is committed to an ambitious modernization plan, Head towards 2030, supported by the State and all local authorities.

More information on www.ap-hm.fr.

About Aix Marseille University and CRMB

The largest multidisciplinary French-speaking university, Aix-Marseille University welcomes more than 80,000 students and nearly 8,000 staff on five large campuses of international standards.

The Biological and Medical Magnetic Resonance Center (CRMBM, UMR n°7339) associated with the CNRS and Aix-Marseille University is specialized in the development of methods and applications in magnetic resonance imaging and spectroscopy. The CRMBM has state-of-the-art equipment for magnetic resonance imaging in animals and humans, including ultra-high field devices (7T human).

The laboratory develops translational research from animals to humans in order to better characterize the physiology and pathophysiology of the central nervous, musculoskeletal and cardiovascular systems. Recently, research activities related to artificial intelligence have also been developed in connection with these themes. Research is conducted in collaboration with a large number of academic and industrial partners at the regional, national and international levels through ambitious research projects funded by academic contracts, foundations, patient associations and international programs.

More information on www.univ-amu.fr

Intrasense

Salomé Sylvestre
Communications Manager
Tél. : +334 67 13 01 30

investisseurs@intrasense.fr

SATT Sud-Est

Clara Azzaro
Communications Manager
Tél. : +33 7 81 08 08 55

clara.azzaro@sattse.com

AP-HM

Caroline Pérabut
Communications Manager

caroline.perabut@ap-hm.fr

NewCap

Thomas Grojean
Financial Communication
and investor relations
Tél. : +331 44 71 20 40

intrasense@newcap.eu